• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Medtronic plc.

    5/28/25 5:30:45 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email
    SD 1 formsd-2024conflictminerals.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM SD
    Specialized Disclosure Report
     
     
    Medtronic plc
    (Exact name of Registrant as Specified in its Charter)
     
     
     
    Ireland 1-36820 98-1183488
    (State or other jurisdiction
    of incorporation)
     (Commission
    File Number)
     (IRS Employer
    Identification No.)
     
    Building Two, Parkmore Business Park West
    Galway, Ireland
     n/a
    (Address of principal executive offices) (Zip Code)

     
    Thierry Piéton 763-514-4000
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.




    INFORMATION TO BE INCLUDED IN THE REPORT

    Section 1 - Conflict Minerals Disclosure


    Item 1.01 Conflict Minerals Disclosure and Report
    This Form SD of Medtronic plc (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024
    A copy of Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and details the due diligence measures undertaken during the reporting period by the Company on a consolidated basis. A copy of the Conflict Minerals Report is also publicly available through the Company’s website by clicking the SEC Filings link under the Financials drop-down at www.investorrelations.medtronic.com.
    Item 1.02 Exhibit

    The Company has filed, as an exhibit to this Form SD, the Conflict Minerals Report of the Company required by Item 1.01.

    Section 2 - Exhibits


    Item 2.01 Exhibits

    The following exhibit is filed as part of this report:

    Exhibit 1.01 - Conflict Minerals Report of the Company




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    Medtronic plc
    Date: May 28, 2025By/s/ Thierry Piéton
    Thierry Piéton
    Executive Vice President and Chief Financial Officer




    EXHIBIT INDEX
    Medtronic plc
    Form SD
     
    Exhibit No.  Description
    1.01
      
    Conflict Minerals Report of the Company

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    More analyst ratings

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Medtronic upgraded by Wolfe Research

      Wolfe Research upgraded Medtronic from Underperform to Peer Perform

      6/30/25 7:56:30 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Leerink Partners initiated coverage on Medtronic with a new price target

      Leerink Partners initiated coverage of Medtronic with a rating of Outperform and set a new price target of $110.00

      6/16/25 7:51:25 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic upgraded by Citigroup with a new price target

      Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

      3/4/25 7:37:34 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

      GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

      7/8/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Board appoints Dr. Joon Lee as a new director

      GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

      6/23/25 4:15:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces MiniMed as name for planned New Diabetes Company

      GALWAY, Ireland, June 12, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.   "Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-k

      6/12/25 9:00:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Lee Joon Sup claimed no ownership of stock in the company (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      7/2/25 4:36:21 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Accounting Officer Blomquist Denise L. gifted 310 units of Ordinary Shares, decreasing direct ownership by 3% to 10,143 units (SEC Form 4)

      4 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:30:34 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Kiil Harry Skip claimed ownership of 33,442 units of Ordinary Shares (SEC Form 3)

      3 - Medtronic plc (0001613103) (Issuer)

      6/4/25 4:29:12 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Medtronic plc.

      25-NSE - Medtronic plc (0001613103) (Subject)

      7/2/25 1:17:58 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      6/23/25 4:17:20 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form IRANNOTICE filed by Medtronic plc.

      IRANNOTICE - Medtronic plc (0001613103) (Filer)

      6/20/25 6:46:40 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

      GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

      7/8/25 8:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic Board appoints Dr. Joon Lee as a new director

      GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

      6/23/25 4:15:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/13/24 5:09:43 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/12/24 1:59:55 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/15/23 3:34:14 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MDT
    Financials

    Live finance-specific insights

    See more
    • Medtronic announces cash dividend for fourth quarter of fiscal year 2025

      GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

      3/6/25 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic reports third quarter fiscal 2025 financial results

      Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic

      2/18/25 6:45:00 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic announces cash dividend for third quarter of fiscal year 2025

      GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

      12/5/24 4:30:00 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care